B · Normal
[State Food and Drug Administration approves the marketing of Eltripamide Nasal Spray] On September 3, the State Administration of Drug Administration approved the listing of Eltripamide Nasal Spray (trade name: Xingbitu), a Class 1 innovative drug applied by Milestone Pharmaceuticals Inc., which is used to treat acute symptoms of paroxysmal supraventricular tachycardia (PSVT) in adults and convert them to sinus rhythm. The launch of this drug provides patients with new treatment options.
Comments